Minimally-Invasive Implantation of Left Ventricular Assist Devices Improves the Operative Outcome in Adult Patients with Severe Heart Failure

Purpose Left ventricular assist devices (LVAD) are gaining more importance in the treatment of heart failure. The constant development of novel technologies in this field is being reflected by enhanced and considerably miniaturized LVAD-systems. However from a surgical point of view, complications like bleeding or right ventricular failure with liver impairment are still major hurdles in LVAD-therapy. Therefore, we recently developed a novel minimally invasive LVAD implantation technique in order to minimize complication rates and improve operative outcome. Methods and Materials We reviewed the early outcome of 100 consecutive end-stage heart failure patients (74% male, age 51,6 ± 12,6, DCM 49%, ICM 36%) who recently underwent LVAD (HVAD, HeartWare, USA) implantation in our institution between 2011 and 2012. Patients who were operated conventionally by a median sternotomy (group A; n = 65) were compared to patients receiving a minimal invasive upper hemisternotomy combined with an anterolateral thoracotomy (group B; n = 35). Results Intra-hospital-mortality was lower in group B (12,3% vs. 8,6%). ICU stay was significantly lower ( p p ) lower in group B (18.5% vs. 5,7%). Postoperative glutamate dehydrogenase (GLDH) levels were also significantly ( p Conclusions Our data show that the applied minimally invasive LVAD-implantation technique improves the early postoperative outcome by improving survival and reducing bleeding events, liver impairment and postoperative ICU stay of terminal heart failure patients.